BRAF V600E mutations occur in 8–12% of metastatic colorectal cancers (mCRCs)1,2; the presence of these mutations has emerged as a distinct subtype that is characterized by poor prognosis compared with wild-type disease and resistance to standard chemotherapy regimens1,2. This evidence concerns the gene BRAF and metastatic colorectal cancer.